PDGFR
Platelet-derived growth factor receptor
PDGFR (Platelet-derived growth factor receptors) are cell surface tyrosine kinase receptors for members of the platelet-derived growth factor (PDGF) family. PDGF subunits -A and -B are important factors regulating cell proliferation, cellular differentiation, cell growth, development and many diseases including cancer. There are two forms of the PDGFR: PDGFR alpha and PDGFR beta.
PDGFR Isoform Specific Products
All Product Categories
-
PDGFR Inhibitors
(270)
View all products
-
PDGFR Antagonist
(1)
View all products
-
PDGFR Activators
(3)
View all products
-
PDGFR Modulators
(2)
View all products
-
PDGFR Chemical
(1)
View all products
-
PDGFR Control
(1)
View all products
-
PDGFR Ligands
(2)
View all products
-
PDGF-R-alpha Proteins
(12)
View all products
-
PDGF-R-beta Proteins
(8)
View all products
-
PDGFR Proteins
(22)
View all products
-
PDGFR Related Products (310)
Related Products (310)
-
Recombinant Proteins (22)
-
Antibodies (5)
-
PDGFR Isoform Comparison
-
Pdgfra Mouse Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS10255Pdgfra Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pdgfra gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
MET/PDGFRA-IN-1
0 ImagesCat. No.: HY-149510CAS No.: 3125694-48-3MET/PDGFRA-IN-1 (compound 8c) is a MET and PDGFRA protein inhibitor (IC50: 36 μM for MET). MET/PDGFRA-IN-1 inhibits MET phosphorylation and induces cell apoptosis. MET/PDGFRA-IN-1 inhibits proliferation of MET-positive cells (IC50s: 15.3, 19.0, 22.0, 25.6, 21.0, 31.5 μM for AsPc-1, EBC-1, MKN-45, Mia-Paca-2, HT-29, K562 cells respectively).
-
PDGFRα/FLT3-ITD-IN-2
0 ImagesCat. No.: HY-145903CAS No.: 2761259-09-8
-
IHMT-TRK-284
0 ImagesCat. No.: HY-146697CAS No.: 2416844-79-4
-
Henatinib
0 ImagesCat. No.: HY-13645CAS No.: 1239269-51-2Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities. Henatinib inhibits the activity of VEGFR-2, c-kit, PDGFR with IC50 values of 0.6 nM, 3.3 nM and 41.5 nM, respectively. Henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signal pathway in human umbilical vein endothelial cells (HUVECs).
-
KN1022
0 ImagesCat. No.: HY-149462CAS No.: 205255-11-4KN1022 an inhibitor of phosphorylation of platelet-derived growth factor receptor (PDGFR) with IC50 of 0.24 μM.
-
Pazopanib Hydrochloride (Standard)
0 ImagesSynonyms: GW786034 Hydrochloride (Standard)Pazopanib (Hydrochloride) (Standard) is the analytical standard of Pazopanib (Hydrochloride). This product is intended for research and analytical applications. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
-
Regorafenib-13C,d3
0 ImagesCat. No.: HY-10331S1Synonyms: BAY 73-4506-13C,d3
-
Biotin-PDGFRβ Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70803PDGF-BB/PDGFRβ signaling plays an important role during vascularization by mediating pericyte recruitment to the vasculature, promoting the integrity and function of vessels. Biotin-PDGFRβ Recombinant Human Active Protein Kinase is a recombinant PDGFRβ protein that can be used to study PDGFRβ-related functions, and is biotinylated.
-
Tyrphostin A9 (Standard)
0 ImagesSynonyms: Tyrphostin 9 (Standard); Malonoben (Standard)Tyrphostin A9 (Standard) is the analytical standard of Tyrphostin A9. This product is intended for research and analytical applications. Tyrphostin A9, a PDGFR inhibitor, is a potent inducer of mitochondrial fission. Tyrphostin A9 emerged as the most potent and selective of 51 tyrosine kinase inhibitors tested against the TNF-induced respiratory burst. Tyrphostin A9 has anti-influenza virus activities.
-
Cediranib maleate (Standard)
0 ImagesSynonyms: AZD-2171 maleate (Standard)Cediranib (maleate) (Standard) is the analytical standard of Cediranib (maleate). This product is intended for research and analytical applications. Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
-
Masitinib mesylate (Standard)
0 ImagesSynonyms: AB-1010 mesylate (Standard)Masitinib (mesylate) (Standard) is the analytical standard of Masitinib (mesylate). This product is intended for research and analytical applications. Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity.
-
Toceranib phosphate (Standard)
0 ImagesCat. No.: HY-10330ARCAS No.: 874819-74-6Synonyms: SU11654 phosphate (Standard); PHA 291639E phosphate (Standard)Toceranib phosphate (Standard) is the analytical standard of Toceranib phosphate (HY-10330A). This product is intended for research and analytical applications. Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .
-
RPR-101511
0 ImagesCat. No.: HY-172228CAS No.: 146535-06-0RPR-101511 is a 3-substituted quinoline derivative. RPR-101511 is a PDGF receptor tyrosine kinase inhibitor (IC50: 0.001-0.02 μM).
-
Orantinib (Standard)
0 ImagesCat. No.: HY-10517RCAS No.: 252916-29-3Synonyms: SU6668 (Standard); TSU-68 (Standard)Orantinib (Standard) is the analytical standard of Orantinib (HY-10517). This product is intended for research and analytical applications. Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with Kis of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively.
-
Dovitinib (Standard)
0 ImagesSynonyms: CHIR-258 (Standard); TKI258 (Standard)Dovitinib (Standard) is the analytical standard of Dovitinib. This product is intended for research and analytical applications. Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity.
-
Amuvatinib (Standard)
0 ImagesSynonyms: MP470 (Standard); HPK 56 (Standard)Amuvatinib (Standard) is the analytical standard of Amuvatinib. This product is intended for research and analytical applications. Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity.
-
(Z)-Orantinib (Standard)
0 ImagesCat. No.: HY-10517ARCAS No.: 210644-62-5Synonyms: (Z)-SU6668 (Standard); (Z)-TSU-68 (Standard)(Z)-Orantinib (Standard) is the analytical standard of (Z)-Orantinib (HY-10517A). This product is intended for research and analytical applications. (Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 μM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
-
AGL 2043
0 ImagesCat. No.: HY-112350CAS No.: 226717-28-8AGL 2043 is an effective inhibitor of PDGFR (IC50=0.8 μM) and TEL-PDGFR kinases, as well as FLT3 and KIT kinases. AGL 2043 can effectively inhibit porcine cardiac smooth muscle cell proliferation and balloon-induced vascular stenosis, and is suitable for development as an anti-restenotic and anticancer agent.
